Innovative structural color coatings from Chiba University combine hydrophobic melanin particles, offering long-lasting ...

Takeda Canada Inc., the Canadian organization of Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that non-profit ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

NET PROFIT FORECAST: Takeda is expected to post a 59% drop in net profit to 43.58 billion yen, equivalent to $280.2 million, for the three months ended Dec. 31, according to a poll of analysts by data ...

In a step towards developing advanced materials for functional coatings, a research group from Japan, developed a technology ...

Takeda Pharmaceutical Co. will get to arbitrate claims by a plaintiff that accused the company of delaying the generic ...

FILE - Scottie Scheffler gestures on the 18th green at Pebble Beach Golf Links during the third round of the AT&T Pebble ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

The comments mark the latest in a number of trade-related threats unleashed by Trump in recent days. Trump said he plans to ...

Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...